Objective: Everolimus is positioned as second-line treatment for metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitors. We investigated retrospectively the efficacy and safety of everolimus in Japanese patients with advanced renal cell carcinoma in the clinical setting. Methods: Nineteen patients who discontinued treatment with vascular endothelial growth factor receptor-tyrosine kinase inhibitors because of disease progression or adverse events were administered everolimus. We evaluated progression-free survival, overall survival and tumor response rate of everolimus treatment. We also compared laboratory abnormalities and adverse events of everolimus treatment with those of prior vascular endothelial growth factor receptor-tyrosine kinase inhibitors therapy. Results: In all patients, median progression-free survival was 8.4 months and median overall survival was not reached at 25 months. The best objective response was complete response in 1 patient and stable disease in 15 patients. Eleven patients (58%) were intolerant and 8 (42%) were refractory to prior vascular endothelial growth factor receptor-tyrosine kinase inhibitors treatment. Median overall survival was significantly longer (P , 0.01) in vascular endothelial growth factor receptor-tyrosine kinase inhibitor-intolerant (.25 months) than in vascular endothelial growth factor receptor-tyrosine kinase inhibitor-refractory subjects (4.3 months), and median progression-free survival tended to be better (P ¼ 0.06) in vascular endothelial growth factor receptor-tyrosine kinase inhibitor-intolerant (10.0 months) than in vascular endothelial growth factor receptor-tyrosine kinase inhibitor-refractory subjects (2.5 months). Two patients discontinued everolimus treatment because of adverse events. Conclusions: In this study, the overall survival and progression-free survival were better in vascular endothelial growth factor receptor-tyrosine kinase inhibitor-intolerant than in vascular endothelial growth factor receptor-tyrosine kinase inhibitor-refractory subjects. The adverse event profiles of everolimus and vascular endothelial growth factor receptor-tyrosine kinase inhibitors were different. Patients intolerant to vascular endothelial growth factor receptortyrosine kinase inhibitors may tolerate everolimus well and have greater survival benefit from switching to everolimus than those refractory to vascular endothelial growth factor receptortyrosine kinase inhibitors.
INTRODUCTION
Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase consisting of two distinct signaling complexes, mTORC1 and mTORC2 (1) . The role of mTORC1 is to regulate cell growth and protein synthesis in response to stimulation by phosphorylating S6 kinase (2) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) (3) . The mTORC1 inhibitors suppress the growth of von HippelLindau (VHL)-deficient clear cell kidney cancers by inhibiting hypoxia-inducible factor 1a (HIF1-a) translation (4) . Everolimus, a mTORC1 inhibitor, has been evaluated in a double-blind, placebo-controlled (RECORD-1) trial in patients with metastatic renal cell carcinoma (RCC) that had progressed on prior treatment with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKI). The RECORD-1 study demonstrated that treatment with everolimus prolonged progression-free survival (PFS) compared with placebo (4.9 vs. 1.9 months) (5) . As a result, the European Association of Urology (EAU) guidelines and the National Comprehensive Cancer Network (NCCN) guidelines recommend everolimus as a second-line treatment after failure of treatment with VEGFR-TKI (6, 7) . In 2010, everolimus was also approved for metastatic RCC in Japan. A subgroup analysis of Japanese patients from the RECORD-1 study showed good tolerability and prolongation of PFS (5.75 months) (8) . However, only a small number of Japanese patients were enrolled in the RECORD-1 study and the eligibility criteria were strict. Therefore, it remains unclear whether the trial results reflect real clinical situations.
The aims of the present study were to evaluate the efficacy of everolimus in the clinical setting and to assess safety by comparing laboratory abnormalities, adverse events and performance status (PS) during everolimus treatment with those during prior VEGFR-TKI therapy.
PATIENTS AND METHODS

PATIENTS
Nineteen patients with advanced RCC treated with everolimus between April 2010 and June 2012 were evaluated. All patients were treated previously with VEGFR-TKI and discontinued treatment because of disease progression or adverse events. During everolimus therapy, dose interruption and reduction to 5 mg/day were permitted if Grades 3 or 4 adverse event occurred.
EFFICACY AND SAFETY
The primary end point was PFS on everolimus treatment. Secondary endpoints were tumor response rate, safety and overall survival (OS). PFS and OS were estimated by the Kaplan -Meier method. Univariate and multivariate analyses were performed by log-rank test and the Cox proportional hazards model, respectively. Treatment failure was defined as disease progression, discontinuation due to intolerance or cancer death. Tumor response was evaluated by the Response Evaluation Criteria (RECIST) ver. 1.1. Safety was assessed using the National Cancer Center Common Toxicity Criteria for Adverse Events (CTCAE), ver. 4.0, and compared with that of prior VEGFR-TKI treatment. PS was assessed by Karnofsky Performance Status Scale (KPS), and t-test was used to compare KPS at VEGFR therapy and everolimus treatment. A subgroup analysis was performed to compare subjects intolerant and those refractory to prior VEGFR-TKI treatment. Fisher's exact test or x 2 test and t-test were used to compare patient characteristics and clinical course of subgroups.
RESULTS
PATIENTS
The detailed clinical characteristics of each patient are listed in Table 1 . All 19 patients were refractory (discontinued due to disease progression) or intolerant (discontinued due to adverse event) to prior treatment with VEGFR-TKI. Sixteen patients were males, with median age of 63 (range 43 -83) years. Seventeen patients had KPS rating of 80 -100% (average 87.8 + 3.8%) at the start of previous VEGFR-TKI treatment. According to the Memorial Sloan-Kettering Cancer Center (MSKCC) risk criteria (9) , four patients (21%) were classified into the poor risk group. Two patients had unresectable RCC without metastases, and the other 17 patients had metastatic RCC. The most common sites of metastases were lymph node and lung. Thirteen patients had prior nephrectomy and 2 patients received cytoreductive nephrectomy following administration of sunitinib, and histology showed clear cell RCC in 15 patients. Everolimus was given as second-line therapy in 15 patients previously treated with one VEGFR-TKI, including sunitinib in 11 patients, or as third-line therapy in 4 patients previously treated with multiple VEGFR-TKI such as sorafenib and pazopanib. Case 16 participated in a Phase 2 trial of sorafenib and had continued sorafenib treatment for over 7 years.
EFFICACY
SURVIVAL AND PS OF ALL SUBJECTS
The median follow-up period was 11.4 (range 0.8 -25.6) months. The median PFS was estimated to be 8.4 (range 0.7 -21.1) months and the median OS was not reached at 25 (range 0.7 -23.8) months (Fig. 1a and b) . The best tumor response was complete response in 1 patient, stable disease in 15 patients and progressive disease in 3 patients. Eleven patients discontinued everolimus treatment, including nine with disease progression and two with Grade 3/4 adverse events. Twelve patients were alive at the last follow-up, eight of whom continued everolimus therapy and four of whom were switched to other treatments.
Average KPS at the beginning of VEGFR-TKI treatment was (87.8 + 3.8%) and was reduced significantly (P ¼ 0.03) at the start of everolimus therapy (75.8 + 3.7%), but KPS remained stable during everolimus treatment (72.6 + 5.1%, P ¼ 0.67) (Fig. 2) .
CLINICAL FACTORS PREDICTING SURVIVAL
We performed multivariate analyses on PFS and OS with respect to the prognostic factors used in the RECORD-1 trial [KPS, sex, age, MSKCC risk score, time from initial diagnosis, number of organs involved, sites of metastases (liver, lung, bone, lymph nodes and CNS), prior therapy (radiation, interferon, interleukin), number of prior medications, prior sunitinib, prior sorafenib and laboratory data (corrected calcium, alkaline phosphatase, lactate dehydrogenase (LDH), hemoglobin, platelets, neutrophils)] (5). For PFS, univariate analysis identified poor KPS and bone metastasis as significant predictors, but subsequent multivariate analysis found both to be insignificant. For OS, univariate analysis identified poor KPS, bone metastasis, lymph node metastasis, history of interferon treatment and high corrected calcium level as significant predictors, but subsequent multivariate analysis again found none of them to be independent factors (data not shown).
ANALYSIS OF VEGFR-TKI-INTOLERANT AND VEGFR-TKI-REFRACTORY SUBGROUPS
VEGFR-TKI treatment failure is a clinical indication for switching to everolimus therapy. However, this group of patients includes two populations; those who are refractory and those who are intolerant to VEGFR-TKI. We therefore performed a subgroup analysis by dividing the patients into a VEGFR-TKI-refractory group (n ¼ 8, 42%) and a VEGFR-TKI-intolerant group (n ¼ 11, 58%). The patient background (age, sex, KSKCC risk score, prior VEGFR-TKI therapies, other systemic therapies, radiotherapy, nephrectomy disease sites and common sites of metastasis) of the two groups did not differ significantly, except that prior interferon use was more frequent in VEGFR-TKI refractory patients (data not shown).
The clinical outcomes of the two groups are shown in Table 2 . The median OS was 4.3 months in the VEGFR-TKI refractory group, while the median OS was not reached at 25 months in the VEGFR-TKI intolerant group, with a significant difference between two groups (P , 0.01). Also, PFS tended to be better (P ¼ 0.06) in the TKI-intolerant group (median, 10.0 months) than in the VEGFR-TKI refractory group (median, 2.5 months). Furthermore, all except two patients in the VEGFR-TKI-refractory group were switched to best supportive care (BSC), whereas 3 patients in the VEGFR-TKIintolerant group continued molecular targeted therapy and 1 patient was changed to vaccine therapy. The KPS at the beginning of VEGFR-TKI treatment was significantly (P ¼ 0.03) better in the VEGFR-TKI refractory group than in the VEGFR-TKI-intolerant group (Table 2) . In both group, PS deteriorated at the end of VEGFR-TKI treatment, with no significant difference between two groups. During everolimus treatment, KPS was maintained in both groups.
SAFETY
Safety of everolimus treatment was evaluated and compared with prior VEGFR-TKI treatment (Tables 3 and 4) . The total number of Grades 3 and 4 laboratory abnormalities was greater during everolimus treatment than during prior VEGFR-TKI therapy (27 vs. 20), while the total number of Grades 3 and 4 adverse events was smaller (7 vs. 12). Anemia, hyperglycemia and hypercholesterolemia were more frequently observed during everolimus treatment. Six patients had Grade 3 or 4 anemia, three patient had Grade 3 or 4 hypercholesterolemia and four patients had Grade 3 hyperglycemia. Due to severe adverse events, two patients discontinued everolimus treatment (Case 3 and Case 7). Case 7 had Grade 3 interstitial pneumonitis. Case 3 had Grade 3 elevation of serum creatinine. This patient had acute kidney injury due to prior sunitinib treatment and gradually recovered before the start of everolimus treatment. When everolimus was started, serum creatinine level was elevated again and reached 6.9 mg/dl on the 45th day. After discontinuation of everolimus, serum creatinine decreased slightly but renal dysfunction persisted.
DISCUSSION
In the present study, we retrospectively analyzed the short-term efficacy and safety of everolimus treatment in the clinical setting. VEGFR-TKI treatment failure is an indication of everolimus therapy clinically, and this population consists of patients who are refractory and those who are intolerant to VEGFR-TKI. Therefore, we performed a subgroup analysis to compare VEGFR-TKI-refractory and VEGFR-TKI-intolerant patients.
Our study had a longer median PFS compared with the subgroup analysis of Japanese patients from RECORD-1 trial (8.4 vs. 5.75 months). Multivariate analyses of PFS and OS with 
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Everolimus in advanced RCC refractory or intolerant to TKIs respect to the prognostic factors in the RECORD-1 trial found none of them to be independent factors. The difference in survival between our study and RECORD-1 trial may be due to the following. First, the proportion of VEGFR-TKI-intolerant subjects is much higher in our study (58%) than in RECORD-1 trial (15.5%). Our subgroup analysis found that OS was significantly higher and PFS tended to be higher in VEGFR-TKI intolerant than in refractory subjects, although there was no significant difference in clinical background (except interferon use) between two groups. Together, these would have resulted in better survival in our study than in RECORD-1 trial. Second, in this retrospective study, switching of VEGFR-TKI treatment failure cases to everolimus therapy or BSC was decided by the clinical doctors. During the same period, 18 VEGFR-TKI treatment failure cases were switched to BSC (sorafenib or sunitinib). This group of patients had shorter median OS than our study subjects (10 months vs. median not reached in 90 months). Together with the small number of patients studied, the resulting selection bias may have influenced the results of PFS and OS in our study.
In the present study, 47% of the patients had PS 70% or below at the start of everolimus treatment, which is higher than the everolimus þ BSC group (10%) in RECORD-1 trial. In all subjects, PS was deteriorated significantly by VEGFR-TKI therapy, but was maintained during everolimus treatment. In subgroup analysis, PS at the beginning of everolimus therapy was not different between VEGFR-TKI refractory and intolerant groups, and PS was well preserved in both groups during everolimus treatment, showing good tolerability to everolimus even in patients intolerant to prior VEGFR-TKI treatment.
The complete response rate in our study group was 5% and the stable disease rate was 79%. In RECORD-1 study, the partial response rate was 1.8% and the stable disease rate was 67% (6). Everolimus does not exhibit strong cytoreductive effect. Toschi et al. (10) demonstrated that VHL-deficient clear cell carcinomas express both HIF-1-a and HIF2-a; HIF1-a translation is dependent on mTORC1 pathway and HIF2-a is dependent on mTORC2 pathway. Everolimus targets mTORC1 pathway but does not inhibit mTORC2, and therefore is assumed to have incomplete antitumor activity. Thus, the clinical benefit of everolimus may be regarded as maintaining stable disease.
In the clinical setting, we encountered many patients who became refractory to first-line treatment with VEGFR-TKI and showed disease progression. The mechanism of resistance to VEGFR-TKI has been investigated, Huang et al. (11) demonstrated that IL-8 overexpression is associated with development of sunitinib resistance in clear cell RCC xenograft models. Zama et al. (12) reported that patients resistant to sunitinib potentially benefit from sunitinib retreatment and suggested that a longer interval before rechallenging with sunitinib may lead to a better response. Several clinical guidelines recommend everolimus as a second-line treatment after failure of VEGFR-TKI. Prolonged disease control by mTOR inhibitors may allow time off VEGFR-TKI therapy and contribute to potential benefit from third-line therapy by VEGFR-TKI. Another benefit of everolimus treatment is that it maintains PS in RCC patients. Cachexia syndrome is a risk factor for cancer death. Robert et al. (13) demonstrated that mTOR controls interleukin-10 level in a cachexia murine model, and suggested that inhibition of mTOR may ameliorate the severity of cachexia syndrome. Clinical trials have shown that sirolimus, an mTORC1 inhibitor, prolonged survival in patients with advanced RCC and multiple risk factors predictive of short survival (14) . Compared with VEGFR-TKI therapy, mTOR inhibitors have little impact on tumor shrinkage but have good tolerability and the benefit of preserving PS, as shown in our study.
In the present clinical study, everolimus was well tolerated compared with prior VEGFR-TKI. The profiles of laboratory abnormalities and adverse events did not overlap with those of prior VEGFR-TKI. Anemia, hyperglycemia and hypercholesterolemia were frequently observed during everolimus treatment. Interestingly, the PFS of 16 patients with hyperglycemia was longer than the others with no hyperglycemia (P ¼ 0.01). The PFS of 10 patients with hyperlipidemia during everolimus treatment was also longer than those with no hyperlipidemia (P ¼ 0.001). Vander Heiden et al. (15) reported that cancer cells depend on aerobic glycolysis. The PI3 kinase pathway is involved in cell surface expression of nutrient transporters, which increases uptake of amino acid and glucose (16) . Moreover, mTORC1 presumably plays an important role in fat metabolism (17) . While a correlation between inhibition of tumor proliferation and metabolic disorders induced by mTOR inhibition has not been confirmed, it is possible that metabolic disorder during everolimus treatment may be a clinical biomarker predicting response to everolimus, similar to hypertension as a predictor of response to VEGFR-TKI (18) . Two patients discontinued everolimus treatment because of adverse events. One patient had Grade 3 interstitial pneumonitis and the other one had severe acute kidney injury. Everolimus has been reported to have less severe nephrotoxicities, and this drug has been used as an immunosuppressant in recipients of organ transplants. Lieberthal et al. (19) speculated that inhibitors of mTOR may slow the progression of renal failure in diabetic nephropathy and other forms of chronic kidney disease. On the other hand, they also pointed out that mTOR activity increases after acute kidney injury and inhibition of mTOR delays renal recovery and repair. Everolimus may have to be used with caution in patients showing a delay in recovery from acute kidney injury related to prior therapy.
Our study has several limitations. First, it was a retrospective study with only 19 cases. The number of cases is too small, with potential selection bias. Second, the follow-up period was short (median 11.4 months). Third, not all patients had histologically proven RCC.
In conclusion, the present study conducted in the clinical setting showed that everolimus was well tolerated compared with prior VEGFR-TKI in patients with advanced RCC. Median PFS and OS in this study were much better than those of the RECORD-1 trial. A subgroup analysis showed significantly better OS in VEGFR-TKI intolerant than in VEGFR-TKI refractory patients treated with everolimus, and PS was maintained during therapy in both groups. While intolerance and refractoriness to VEGFR-TKI are both indications of everolimus in the clinical setting, VEGFR-TKI-intolerant patients tolerate everolimus well and may have greater survival benefit from switching to everolimus than VEGFR-TKI-refractory patients. Further studies and longer follow-up period are warranted to verify whether everolimus treatment contributes to prolongation of total OS evaluated from the initiation of first-line therapy.
